These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data.
    Author: Wylie ME, Miller MD, Shear MK, Little JT, Mulsant BH, Pollock BG, Reynolds CF.
    Journal: J Geriatr Psychiatry Neurol; 2000; 13(1):43-8. PubMed ID: 10753007.
    Abstract:
    The authors present data from an open trial of fluvoxamine (median daily dosage: 200 mg) in the treatment of generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder in 19 older outpatients (mean age = 66.8). Of the 12 subjects completing the 21-week trial, 8 achieved a good response (50% reduction in symptom measures) and 7 were rated as much or very much improved. Fluvoxamine pharmacotherapy also had a significant effect in reducing comorbid depressive symptoms and in increasing levels of functioning. These data support the effectiveness of fluvoxamine in older subjects with anxiety disorders (particularly generalized anxiety disorder) and warrant further double-blind, placebo-controlled evaluation.
    [Abstract] [Full Text] [Related] [New Search]